{"timeline":{"headline":"Neurobiology of Opioid Dependence: 2 - 2","type":"default","text":"History of NCT00000193","startDate":"2005,06,23","date": [{"startDate":"2005,06,23","headline":"View of NCT00000193 on 2005_06_23","text":"<table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_23</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Study design</th><td>Placebo Control</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Behavioral, subjective, measures of naloxone-preci\n      </td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Phsyiological, neuroendocrine measures of naloxone\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1996-01\n      </td>\n</tr>\n<tr>\n<th>Last data entry date</th><td>\n         1996-10\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th>Expected enrollment</th><td>0</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,06,30","headline":"View of NCT00000193 on 2005_06_30","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_30</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Study design</th><td>Placebo Control</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Behavioral, subjective, measures of naloxone-preci\n      </td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Phsyiological, neuroendocrine measures of naloxone\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1996-01\n      </td>\n</tr>\n<tr>\n<th>Last data entry date</th><td>\n         1996-10\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th>Expected enrollment</th><td>0</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span><table class=\"info\"><tr><th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td></tr><tr><th>Updated:</th><td>2005_06_<del style=\"background:#ffe6e6;\">2</del><span>3</span><ins style=\"background:#e6ffe6;\">0</ins><span></span></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Descriptive Information</h2></th></tr><tr><th>Brief title</th><td><p>Neurobiology of Opioid Dependence: 2 - 2</p></td></tr><tr><th>Official title</th><td><p>Neurobiology of Opioid Dependence: 2</p></td></tr><tr><th>Brief summary</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p></td></tr><tr><th>Detailed description</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p></p></td></tr><tr><th>Phase</th><td>Phase 2</td></tr><tr><th>Study type</th><td>Interventional</td></tr><tr><th>Study design</th><td>Treatment</td></tr><tr><th>Study design</th><td>Double Blind</td></tr><tr><th>Study design</th><td>Placebo Control</td></tr><tr><th>Primary outcome</th><td>Measure:          Behavioral, subjective, measures of naloxone-preci      </td></tr><tr><th>Primary outcome</th><td>Measure:          Phsyiological, neuroendocrine measures of naloxone      </td></tr><tr><th>Condition</th><td>         Opioid-Related Disorders      </td></tr><tr><th>Intervention</th><td><div>Drug: Gamma hydroxybutyric</div></td></tr><tr><th>Reference</th><td><div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div><div>MEDLINE: </div></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Recruitment Information</h2></th></tr><tr><th>Status</th><td>            Completed         </td></tr><tr><th>Start date</th><td>         1996-01      </td></tr><tr><th>Last data entry date</th><td>         1996-10      </td></tr><tr><th>Criteria</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p>Please contact site for information.</p></td></tr><tr><th>Gender</th><td>            Male         </td></tr><tr><th>Minimum age</th><td>N/A</td></tr><tr><th>Maximum age</th><td>N/A</td></tr><tr><th>Healthy volunteers</th><td>No</td></tr><tr><th>Expected enrollment</th><td>0</td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Administrative Data</h2></th></tr><tr><th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td></tr><tr><th>Organization study ID</th><td>NIDA-00191-2</td></tr><tr><th>Secondary ID</th><td>            K20-00191-2         </td></tr><tr><th>Sponsor</th><td>               National Institute on Drug Abuse (NIDA)            </td></tr><tr><th>Collaborator</th><td>               Yale University            </td></tr><tr><th>Health Authority</th><td>               United States: Federal Government         </td></tr></table></span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,12,08","headline":"View of NCT00000193 on 2005_12_08","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_12_08</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Study design</th><td>Placebo Control</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Behavioral, subjective, measures of naloxone-preci\n      </td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Phsyiological, neuroendocrine measures of naloxone\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1996-01\n      </td>\n</tr>\n<tr>\n<th>Last data entry date</th><td>\n         1996-10\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th>Expected enrollment</th><td>0</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span><table class=\"info\"><tr><th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td></tr><tr><th>Updated:</th><td>2005_<del style=\"background:#ffe6e6;\">06_30</del><ins style=\"background:#e6ffe6;\">12_08</ins><span></span></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Descriptive Information</h2></th></tr><tr><th>Brief title</th><td><p>Neurobiology of Opioid Dependence: 2 - 2</p></td></tr><tr><th>Official title</th><td><p>Neurobiology of Opioid Dependence: 2</p></td></tr><tr><th>Brief summary</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p></td></tr><tr><th>Detailed description</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p></p></td></tr><tr><th>Phase</th><td>Phase 2</td></tr><tr><th>Study type</th><td>Interventional</td></tr><tr><th>Study design</th><td>Treatment</td></tr><tr><th>Study design</th><td>Double Blind</td></tr><tr><th>Study design</th><td>Placebo Control</td></tr><tr><th>Primary outcome</th><td>Measure:          Behavioral, subjective, measures of naloxone-preci      </td></tr><tr><th>Primary outcome</th><td>Measure:          Phsyiological, neuroendocrine measures of naloxone      </td></tr><tr><th>Condition</th><td>         Opioid-Related Disorders      </td></tr><tr><th>Intervention</th><td><div>Drug: Gamma hydroxybutyric</div></td></tr><tr><th>Reference</th><td><div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div><div>MEDLINE: </div></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Recruitment Information</h2></th></tr><tr><th>Status</th><td>            Completed         </td></tr><tr><th>Start date</th><td>         1996-01      </td></tr><tr><th>Last data entry date</th><td>         1996-10      </td></tr><tr><th>Criteria</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p>Please contact site for information.</p></td></tr><tr><th>Gender</th><td>            Male         </td></tr><tr><th>Minimum age</th><td>N/A</td></tr><tr><th>Maximum age</th><td>N/A</td></tr><tr><th>Healthy volunteers</th><td>No</td></tr><tr><th>Expected enrollment</th><td>0</td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Administrative Data</h2></th></tr><tr><th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td></tr><tr><th>Organization study ID</th><td>NIDA-00191-2</td></tr><tr><th>Secondary ID</th><td>            K20-00191-2         </td></tr><tr><th>Sponsor</th><td>               National Institute on Drug Abuse (NIDA)            </td></tr><tr><th>Collaborator</th><td>               Yale University            </td></tr><tr><th>Health Authority</th><td>               United States: Federal Government         </td></tr></table></span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2013,09,26","headline":"View of NCT00000193 on 2013_09_26","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2013_09_26</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: Behavioral, subjective, measures of naloxone-preci</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: Phsyiological, neuroendocrine measures of naloxone</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>Withdrawn</td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1993-01\n      </td>\n</tr>\n<tr>\n<th>Last follow-up date</th><td>\n         1998-01\n      \n      (Actual)\n  </td>\n</tr>\n<tr>\n<th>Primary completion date</th><td>\n         1998-01\n      \n      (Actual)\n  </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>Yale University</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>K20DA000191\n      (US NIH Grant Number)\n    </td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span><table class=\"info\"><tr><th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td></tr><tr><th>Updated:</th><td>20<del style=\"background:#ffe6e6;\">05_12_08</del><ins style=\"background:#e6ffe6;\">13_09_26</ins><span></span></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Descriptive Information</h2></th></tr><tr><th>Brief title</th><td><p>Neurobiology of Opioid Dependence: 2 - 2</p></td></tr><tr><th>Official title</th><td><p>Neurobiology of Opioid Dependence: 2</p></td></tr><tr><th>Brief summary</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p></td></tr><tr><th>Detailed description</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p></p></td></tr><tr><th>Phase</th><td>Phase 2</td></tr><tr><th>Study type</th><td>Interventional</td></tr><tr><th>Study design</th><td>Treatment</td></tr><tr><th>Study design</th><td>Double Blind</td></tr><tr><del style=\"background:#ffe6e6;\"></del><th><del style=\"background:#ffe6e6\">Study design</del></th><del style=\"background:#ffe6e6\"></del><td><del style=\"background:#ffe6e6\">Placebo Control</del></td><del style=\"background:#ffe6e6\"></del></tr><del style=\"background:#ffe6e6\"></del><tr><del style=\"background:#ffe6e6\"></del><span></span><th>Primary outcome</th><td>Measure: <del style=\"background:#ffe6e6;\"> </del><span>Behavioral, subjective, measures of naloxone-preci</span><del style=\"background:#ffe6e6;\"> </del><span></span></td></tr><tr><th>Primary outcome</th><td>Measure: <del style=\"background:#ffe6e6;\"> </del><span>Phsyiological, neuroendocrine measures of naloxone</span><del style=\"background:#ffe6e6;\"> </del><span></span></td></tr><tr><th>Condition</th><td>         Opioid-Related Disorders      </td></tr><tr><th>Intervention</th><td><div>Drug: Gamma hydroxybutyric</div><ins style=\"background:#e6ffe6;\"><p></p></ins><span></span></td></tr><tr><th>Reference</th><td><div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div><div>MEDLINE: </div></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Recruitment Information</h2></th></tr><tr><th>Status</th><td><del style=\"background:#ffe6e6;\">            Completed         </del><ins style=\"background:#e6ffe6;\">Withdrawn</ins><span></span></td></tr><tr><th>Start date</th><td>         199<del style=\"background:#ffe6e6;\">6</del><ins style=\"background:#e6ffe6;\">3</ins><span>-01      </span></td></tr><tr><th>Last <del style=\"background:#ffe6e6;\">data entry</del><ins style=\"background:#e6ffe6;\">follow-up date</ins></th><td>         1998-01            (Actual)  </td></tr><tr><th>Primary completion<span> date</span></th><td>         199<del style=\"background:#ffe6e6;\">6-10</del><ins style=\"background:#e6ffe6;\">8-01</ins><span> </span><ins style=\"background:#e6ffe6;\">      (Actual)  </ins><span></span></td></tr><tr><th>Criteria</th></tr><tr><td class=\"bigdent\" colspan=\"2\"><p>Please contact site for information.</p></td></tr><tr><th>Gender</th><td>            Male         </td></tr><tr><th><del style=\"background:#ffe6e6;\">Minimum age</del></th><del style=\"background:#ffe6e6\"></del><td><del style=\"background:#ffe6e6\">N/A</del></td><del style=\"background:#ffe6e6\"></del></tr><del style=\"background:#ffe6e6\"></del><tr><del style=\"background:#ffe6e6\"></del><th><del style=\"background:#ffe6e6\">Maximum age</del></th><del style=\"background:#ffe6e6\"></del><td><del style=\"background:#ffe6e6\">N/A</del></td><del style=\"background:#ffe6e6\"></del></tr><del style=\"background:#ffe6e6\"></del><tr><del style=\"background:#ffe6e6\"></del><th><del style=\"background:#ffe6e6\">Healthy volunteers</del></th><del style=\"background:#ffe6e6\"></del><td><del style=\"background:#ffe6e6\">No</del></td><del style=\"background:#ffe6e6\"></del></tr><del style=\"background:#ffe6e6\"></del><tr><del style=\"background:#ffe6e6\"></del><th><del style=\"background:#ffe6e6\">Expected enrollment</del></th><del style=\"background:#ffe6e6\"></del><td><del style=\"background:#ffe6e6\">0</del><ins style=\"background:#e6ffe6;\">Healthy volunteers<td>No<span></span></td></ins></td></tr><tr><th class=\"section\" colspan=\"2\"><h2>Administrative Data</h2></th></tr><tr><th>Organization name</th><td><del style=\"background:#ffe6e6;\">National Institute on Drug Abuse (NIDA)</del><ins style=\"background:#e6ffe6;\">Yale University</ins><span></span></td></tr><tr><th>Organization study ID</th><td>NIDA-00191-2</td></tr><tr><th>Secondary ID</th><td><ins style=\"background:#e6ffe6;\">K20DA000191      (US NIH Grant Number)    </ins></td></tr><tr><th>Secondary ID</th><td><span></span><del style=\"background:#ffe6e6;\"> </del><span> </span><ins style=\"background:#e6ffe6;\"> </ins><span>K20-00191-2         </span></td></tr><tr><th>Sponsor</th><td><ins style=\"background:#e6ffe6;\">               Yale University            </ins></td></tr><tr><th>Collaborator</th><td><span>               National Institute on Drug Abuse (NIDA)            </span></td></tr><tr><th>Collaborator</th><td>               Yale University            </td></tr><tr><th>Health Authority</th><td>               United States: Federal Government         </td></tr></table></span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}}]}}